MX2009005725A - Methods and compositions for treating and monitoring treatment of il-13-associated disorders. - Google Patents

Methods and compositions for treating and monitoring treatment of il-13-associated disorders.

Info

Publication number
MX2009005725A
MX2009005725A MX2009005725A MX2009005725A MX2009005725A MX 2009005725 A MX2009005725 A MX 2009005725A MX 2009005725 A MX2009005725 A MX 2009005725A MX 2009005725 A MX2009005725 A MX 2009005725A MX 2009005725 A MX2009005725 A MX 2009005725A
Authority
MX
Mexico
Prior art keywords
compositions
treating
methods
associated disorders
monitoring treatment
Prior art date
Application number
MX2009005725A
Other languages
Spanish (es)
Inventor
Marion T Kasaian
Samuel J Goldman
Donald G Raible
Timothy A Cook
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009005725A publication Critical patent/MX2009005725A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

Methods and compositions for treating and/or monitoring treatment of IL-13-associated disorders or conditions are disclosed.
MX2009005725A 2006-12-11 2007-12-11 Methods and compositions for treating and monitoring treatment of il-13-associated disorders. MX2009005725A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87433306P 2006-12-11 2006-12-11
US92593207P 2007-04-23 2007-04-23
PCT/US2007/025418 WO2008073463A2 (en) 2006-12-11 2007-12-11 Methods and compositions for treating and monitoring treatment of il-13-associated disorders

Publications (1)

Publication Number Publication Date
MX2009005725A true MX2009005725A (en) 2009-08-24

Family

ID=39295599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005725A MX2009005725A (en) 2006-12-11 2007-12-11 Methods and compositions for treating and monitoring treatment of il-13-associated disorders.

Country Status (7)

Country Link
EP (1) EP2089057A2 (en)
JP (1) JP2010512402A (en)
BR (1) BRPI0720280A2 (en)
CA (1) CA2672215A1 (en)
MX (1) MX2009005725A (en)
RU (1) RU2009120202A (en)
WO (1) WO2008073463A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
WO2008131376A2 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JP2012506695A (en) * 2008-08-20 2012-03-22 ヤンセン バイオテツク，インコーポレーテツド Modified anti-IL-13 antibodies, compositions, methods, and uses
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
DE102011006809A1 (en) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Use of an agent of antibodies and / or insulin-like growth factor antagonists
US9511150B2 (en) 2011-07-19 2016-12-06 CellMosaic, Inc. Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
BR112014000324A8 (en) * 2011-07-19 2019-01-29 Cellmosaic Inc cross-linking reagents, macromolecules, therapeutic conjugates and synthetic methods
US20140248289A1 (en) * 2011-08-26 2014-09-04 University Of Cincinnati Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition
CN107614016B (en) 2015-04-14 2022-06-17 中外制药株式会社 Pharmaceutical composition for preventing and/or treating atopic dermatitis comprising an IL-31 antagonist as an active ingredient
CA3059731A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
WO2019197563A2 (en) * 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1499354A4 (en) * 2002-05-01 2007-07-25 Regeneron Pharma Methods of using cytokine antagonists to treat hiv infection and aids
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes

Also Published As

Publication number Publication date
WO2008073463A2 (en) 2008-06-19
RU2009120202A (en) 2011-01-20
CA2672215A1 (en) 2008-06-19
JP2010512402A (en) 2010-04-22
BRPI0720280A2 (en) 2014-01-28
WO2008073463A3 (en) 2008-10-02
EP2089057A2 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
MX2009005725A (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders.
HUS2100051I1 (en) Compositions and methods of treating cell proliferation disorders
IL258730A (en) Compositions and methods for treatment of microbial disorders
WO2007092622A3 (en) Compositions and methods for treating bone
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
MX2009009761A (en) Compositions and kits for treating influenza.
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
MY165728A (en) Selective glycosidase inhibitors and uses thereof
LT2374472T (en) Compositions and methods for treating ophthalmic disorders
SI1881823T1 (en) Compositions and methods for treatment of eye disorders
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
GB0617734D0 (en) Method of treating peripheral nerve disorders
EP2016187A4 (en) Compositions and methods for enzymatic treatment of lung disorders
MX2010005395A (en) Method of treating arthritis.
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
MX2008011872A (en) Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids.
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
IN2012DN02470A (en)
WO2009126695A3 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
PL2374472T3 (en) Compositions and methods for treating ophthalmic disorders
EP1993612A4 (en) Compositions and methods for treating cognitive disorders
AU2014256372B2 (en) New compositions for treating CMT and related disorders
AU2007903760A0 (en) Composition and method for the treatment or prevention of spinal disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal